Core Viewpoint - Salarius Pharmaceuticals, Inc. will change its corporate name to Decoy Therapeutics Inc. and its shares will trade under the ticker symbol DCOY starting January 8, 2026, reflecting a strategic focus on developing peptide-conjugate therapeutics [2][3]. Company Overview - Decoy Therapeutics is a preclinical-stage biotechnology company utilizing machine learning and AI tools to design and manufacture peptide conjugate drug candidates targeting unmet medical needs, particularly in respiratory viruses and gastrointestinal cancers [7]. Strategic Focus and Plans - The company aims to advance its lead antiviral program into clinical trials while expanding its pipeline and partnership opportunities, with a capital-efficient plan for 2026 [2][4]. - The 2026 priorities include executing a focused approach to achieve multiple value-creating milestones and retaining upside through partnerships and non-dilutive funding [6]. Technology and Innovation - Decoy's proprietary peptide-conjugate platform is designed to selectively intercept and neutralize high-value biological targets, with initial programs addressing pan-coronavirus activity and other viral threats [4]. - The company is leveraging an AI-enabled discovery engine to accelerate candidate selection and is pursuing strategic collaborations with big pharma, technology leaders, and academic institutions [10]. Funding and Partnerships - Decoy has attracted financing from institutional investors and significant capital from various sources, including the Massachusetts Life Sciences Seed Fund and the Google AI startup program [7]. - The lead antiviral program has garnered interest from the Biomedical Advanced Research and Development Authority (BARDA) and global health organizations, positioning the company for additional funding and collaborations [4].

Market Overview - U.S. stocks showed mixed performance with the Dow increasing by 0.66% to 48,244.96, while the Nasdaq Composite fell by 0.65% to 23,315.77 and the S&P 500 dropped by 0.13% to 6,837.50 [1] - Health care shares rose by 1.1%, while communication services stocks decreased by 1.7% [1] Company Performance - On Holding (NYSE:ONON) shares surged over 18% after reporting third-quarter earnings of 54 cents per share, significantly exceeding the analyst consensus estimate of 20 cents per share. The company also reported quarterly sales of $993.036 million, surpassing the consensus estimate of $939.020 million [2] - Leap Therapeutics, Inc. (NASDAQ:LPTX) saw its shares increase by 145% to $1.0708 following better-than-expected third-quarter EPS results [9] - Creative Media & Community Trust Corporation (NASDAQ:CMCT) shares rose 68% to $8.05 after announcing an agreement to sell its lending division [9] - Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) shares gained 24% to $1.2200 after pricing a $7 million underwritten public offering [9] - VisionSys AI Inc. (NASDAQ:VSA) shares plummeted 77% to $0.2960 after announcing a $12 million registered direct offering [9] - Leifras Co., Ltd. (NASDAQ:LFS) shares fell 35% to $7.35 after a significant surge of 576.79% to close at $11.37 in regular trading on Tuesday [9] - Energy Vault Holdings, Inc. (NYSE:NRGV) shares decreased by 23% to $3.29, with Goldman Sachs analyst maintaining a Sell rating and raising the price target from $1.5 to $2 [9] Commodity Market - Oil prices dropped by 4.1% to $58.51, while gold prices increased by 2% to $4,199.90. Silver rose by 4.7% to $53.11, and copper saw a 1.1% increase to $5.1220 [5] International Markets - European shares experienced gains, with the eurozone's STOXX 600 rising by 0.71%, Spain's IBEX 35 Index gaining 1.39%, London's FTSE 100 increasing by 0.12%, Germany's DAX 40 climbing by 1.22%, and France's CAC 40 rising by 1.04% [6] - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 0.43%, Hong Kong's Hang Seng surging 0.85%, China's Shanghai Composite declining by 0.07%, and India's BSE Sensex rising by 0.71% [7] Economic Indicators - The volume of mortgage applications increased by 0.6% from the previous week during the first week of November [10]

Market Overview - U.S. stocks showed mixed performance with the Nasdaq Composite falling over 150 points, while the Dow increased by 0.66% to 48,244.96 and the S&P 500 decreased by 0.13% to 6,837.50 [1] - Health care shares rose by 1.1%, while communication services stocks fell by 1.7% [1] Company Performance - On Holding (NYSE:ONON) shares surged over 18% after reporting third-quarter earnings of 54 cents per share, exceeding the analyst consensus estimate of 20 cents per share, and quarterly sales of $993.036 million, surpassing the consensus estimate of $939.020 million [2] - Leap Therapeutics, Inc. (NASDAQ:LPTX) shares increased by 145% to $1.0708 following better-than-expected third-quarter EPS results [9] - Creative Media & Community Trust Corporation (NASDAQ:CMCT) saw a 68% rise to $8.05 after announcing an agreement to sell its lending division [9] - Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) shares rose by 24% to $1.2200 after pricing a $7 million underwritten public offering [9] - VisionSys AI Inc. (NASDAQ:VSA) shares plummeted by 77% to $0.2960 after announcing a $12 million registered direct offering [9] - Leifras Co., Ltd. (NASDAQ:LFS) shares fell by 35% to $7.35 after a significant surge of 576.79% to close at $11.37 in regular trading on Tuesday [9] - Energy Vault Holdings, Inc. (NYSE:NRGV) shares dropped by 23% to $3.29, with Goldman Sachs maintaining a Sell rating and raising the price target from $1.5 to $2 [9] Commodity Market - Oil prices decreased by 4.1% to $58.51, while gold prices increased by 2% to $4,199.90 [5] - Silver rose by 4.7% to $53.11, and copper increased by 1.1% to $5.1220 [5] International Markets - European shares were generally higher, with the eurozone's STOXX 600 rising by 0.71% and Spain's IBEX 35 Index gaining 1.39% [6] - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 0.43% and Hong Kong's Hang Seng surging by 0.85% [7]

Market Overview - U.S. stocks exhibited mixed trading, with the Dow Jones index increasing by over 400 points, up 0.87% to 48,343.46, while NASDAQ decreased by 0.23% to 23,414.10, and S&P 500 rose by 0.13% to 6,855.64 [1] - Financial shares experienced a notable increase of 1.2%, while communication services stocks fell by 1% [1] Company Performance - IHS Holding Limited reported third-quarter earnings of 44 cents per share, surpassing the analyst consensus estimate of 10 cents per share, and quarterly sales of $455.1 million, exceeding the consensus estimate of $424.395 million [2] Commodity Market - Oil prices decreased by 2.1% to $59.74, while gold prices increased by 0.6% to $4,139.70. Silver rose by 1.9% to $51.71, and copper increased by 1.4% to $5.1370 [4] European Market - European shares showed positive movement, with the eurozone's STOXX 600 rising by 0.7%, Spain's IBEX 35 Index gaining 1.4%, London's FTSE 100 up by 0.1%, Germany's DAX 40 increasing by 1.1%, and France's CAC 40 climbing by 1.2% [5] Asian Market - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 0.43%, Hong Kong's Hang Seng surging 0.85%, China's Shanghai Composite declining by 0.07%, and India's BSE Sensex rising by 0.71% [6] Mortgage Applications - The volume of mortgage applications rose by 0.6% from the previous week during the first week of November [7] Notable Stock Movements - Leap Therapeutics, Inc. shares surged by 87% to $0.8153 following better-than-expected third-quarter EPS results [8] - Creative Media & Community Trust Corporation shares increased by 65% to $7.91 after announcing an agreement to sell its lending division [8] - Salarius Pharmaceuticals, Inc. shares rose by 46% to $1.4201 after pricing a $7 million underwritten public offering [8] - VisionSys AI Inc. shares dropped by 77% to $0.2932 after announcing a $12 million registered direct offering [8] - Leifras Co., Ltd. shares fell by 33% to $7.59 after a significant surge of 576.79% in regular trading on Tuesday [8] - Graphjet Technology shares decreased by 27% to $2.8473 [8]

Group 1: LightPath Technologies Inc - LightPath Technologies Inc (NASDAQ:LPTH) reported better-than-expected first-quarter financial results, leading to a sharp rise in its shares during pre-market trading [1] - The company reported a quarterly loss of 7 cents per share, which was better than the analyst estimate of a 9-cent loss [1] - Quarterly revenue for LightPath Technologies was $15.05 million, surpassing the consensus estimate of $12.66 million [1] - Following the financial results, shares of LightPath Technologies jumped 6.8% to $8.58 in pre-market trading [1] Group 2: Other Stocks in Pre-Market Trading - Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) surged 170% to $2.65 after releasing pricing details for its underwritten public offering [6] - Kandal M Venture Limited (NASDAQ:FMFC) gained 70.4% to $0.9490 after previously falling 8% [6] - Amaze Holdings, Inc. (NYSE:AMZE) rose 68.4% to $0.8934 after extending its partnership with Adobe Express [6] - VCI Global Limited (NASDAQ:VCIG) surged 44.4% to $1.88 after a 27% dip on Tuesday [6] - Clearmind Medicine Inc. (NASDAQ:CMND) gained 27% to $0.5830 after a 32% decline on Tuesday [6] - Lucyd, Inc (NASDAQ:LUCY) surged 23.3% to $1.90 [6] - BILL Holdings, Inc (NYSE:BILL) gained 14.8% to $53.49 [6] - Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) gained 11.7% to $0.8160 after a 5% decline [6] - DBV Technologies SA – ADR (NASDAQ:DBVT) rose 8.7% to $14.50, confirming completion of Phase 3 treatment phase for VIASKIN peanut patch [6] Group 3: Decliners in Pre-Market Trading - MSP Recovery Inc (NASDAQ:MSPR) tumbled 18.2% to $0.46 after a 75% jump on Tuesday [6] - Aspire Biopharma Holdings Inc (NASDAQ:ASBP) declined 16.5% to $0.097 after a 25% dip [6] - Rain Enhancement Technologies Holdco Inc (NASDAQ:RAIN) fell 14.3% to $4.66 after a 10% gain [6] - IRIDEX Corp (NASDAQ:IRIX) shares dipped 13.4% to $1.03 following the announcement of quarterly results [6] - Leifras Co Ltd (NASDAQ:LFS) fell 13.4% to $9.82 after a significant 577% jump on Tuesday [6] - Graphjet Technology (NASDAQ:GTI) fell 12.3% to $3.40 after an 8% decline [6] - ICZOOM Group Inc (NASDAQ:IZM) fell 10.1% to $1.25 after a 34% gain [6] - Biohaven Ltd (NYSE:BHVN) dipped 7.7% to $7.86 after announcing a $150 million offering [6] - Stitch Fix Inc (NASDAQ:SFIX) dipped 4% to $4.21 [6] - Daqo New Energy Corp (NYSE:DQ) fell 3.7% to $34.29 [6]

Market Overview - U.S. stocks showed mixed performance with the Dow Jones index increasing by 0.64% to 47,673.48, while the NASDAQ decreased by 0.79% to 23,340.59 and the S&P 500 fell by 0.23% to 6,817.03 [1] - Energy shares experienced a rise of 1.2%, while information technology stocks saw a decline of 0.9% [1] Company Performance - RealReal Inc (NASDAQ:REAL) shares surged after reporting better-than-expected third-quarter results and providing fourth-quarter sales guidance above estimates, along with an increase in FY25 sales guidance [2] - enGene Holdings Inc (NASDAQ:ENGN) shares increased by 72% to $10.34 following positive Phase 2 LEGEND study data showing a 63% complete response rate [9] - Energy Vault Holdings Inc (NYSE:NRGV) shares rose by 30% to $4.62 after releasing third-quarter results [9] - Surmodics Inc (NASDAQ:SRDX) shares gained 49% to $40.80 after a court denied the FTC's attempt to block GTCR's acquisition [9] - Vor Biopharma Inc (NASDAQ:VOR) shares dropped by 50% to $9.32 due to the announcement of a $100 million public offering [9] - Salarius Pharmaceuticals Inc (NASDAQ:SLRX) shares fell by 50% to $1.00 after announcing a $7 million underwritten public offering [9] - Outset Medical Inc (NASDAQ:OM) shares decreased by 50% to $6.07 following worse-than-expected third-quarter results and a cut in FY25 sales guidance [9] Commodity Market - Oil prices increased by 1.5% to $61.00, while gold rose by 0.3% to $4,134.70 [5] - Silver traded up by 0.8% to $50.730, whereas copper fell by 0.4% to $5.0845 [5] European Market - European shares showed positive movement with the eurozone's STOXX 600 rising by 1.05%, Spain's IBEX 35 Index gaining 1.05%, and London's FTSE 100 increasing by 0.94% [6] Asian Market - Asian markets closed mixed, with Japan's Nikkei 225 down by 0.14%, Hong Kong's Hang Seng up by 0.18%, China's Shanghai Composite down by 0.39%, and India's BSE Sensex up by 0.40% [7]

Market Overview - U.S. stocks showed mixed performance with the Nasdaq Composite falling over 0.4% on Tuesday, while the Dow increased by 0.13% to 47,430.01 and the S&P 500 dropped 0.15% to 6,823.18 [1] - Energy shares rose by 0.9%, while information technology stocks decreased by 0.7% [1] Company Performance - Sea Ltd (NYSE:SE) shares increased by approximately 4% after reporting fiscal Q3 2025 results, with revenue rising 38.3% year-on-year to $5.99 billion, surpassing analyst expectations of $5.65 billion. However, earnings per share were 59 cents, missing the consensus forecast of 77 cents [2] Commodity Market - Oil prices increased by 1.1% to $60.76, gold rose by 0.7% to $4,151.60, silver went up by 1.4% to $51.030, while copper fell by 0.3% to $5.0915 [5] European Market - European shares experienced gains, with the eurozone's STOXX 600 rising by 0.8%, Spain's IBEX 35 Index gaining 0.8%, London's FTSE 100 increasing by 0.8%, Germany's DAX 40 up by 0.2%, and France's CAC 40 climbing by 0.9% [6] Asian Market - Asian markets closed mixed, with Japan's Nikkei 225 down by 0.14%, Hong Kong's Hang Seng up by 0.18%, China's Shanghai Composite declining by 0.39%, and India's BSE Sensex rising by 0.40% [7] Notable Stock Movements - MSP Recovery Inc (NASDAQ:MSPR) shares surged 104% to $0.65 after a previous decline of 15% [9] - Quoin Pharmaceuticals Ltd – ADR (NASDAQ:QNRX) shares increased by 51% to $12.47 following the achievement of target loadings for proprietary delivery technologies [9] - Surmodics Inc (NASDAQ:SRDX) shares rose by 50% to $41.08 after a court denied the FTC's bid to block an acquisition [9] - Vor Biopharma Inc (NASDAQ:VOR) shares dropped 48% to $9.87 due to a public offering announcement of $100 million [9] - Salarius Pharmaceuticals Inc (NASDAQ:SLRX) shares fell 50% to $1.00 after announcing a $7 million public offering [9] - Outset Medical Inc (NASDAQ:OM) shares decreased by 42% to $7.04 after reporting worse-than-expected Q3 results and cutting FY25 sales guidance [9]

Core Insights - Salarius Pharmaceuticals is advancing its Phase 1/2 clinical study of seclidemstat for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) with updates expected later this year [1][2] - The company is progressing with its planned merger with Decoy Therapeutics, which is anticipated to create value through Decoy's innovative peptide conjugate therapeutics platform [2][3] Company Developments - Salarius' seclidemstat is a first-in-class, orally bioavailable LSD1 inhibitor being evaluated at MD Anderson Cancer Center [1][9] - The merger with Decoy Therapeutics is set to create a new entity named Decoy Therapeutics, with Decoy investors expected to own approximately 92.4% of the merged company [2][10] - The combined company will focus on developing peptide conjugate therapeutics for unmet medical needs in respiratory infectious diseases and gastroenterology oncology [3][8] Research Insights - Recent animal studies published highlight the importance of inhibiting LSD1 expression, supporting the potential of SP-2577 in cancer treatment [2][5] - The studies provide insights into the role of KDM1A in regulating neural stem cell fate and its implications in oral squamous cell carcinoma progression [5][6] Future Plans - Decoy Therapeutics plans to advance its lead asset, a pan-coronavirus antiviral, towards an Investigational New Drug (IND) application with the FDA within the next 12 months [6][7] - The ongoing clinical trial at MDACC is expected to report data on patients with MDS and CMML who have previously failed or relapsed after hypomethylating agent therapy [7][9]

Core Insights - Decoy Therapeutics, Inc. is set to merge with Salarius Pharmaceuticals, Inc., with the new entity retaining the name Decoy Therapeutics, following the completion of the merger [1][10] - Renowned MIT Professor Robert S. Langer will join Decoy's Scientific Advisory Board, bringing extensive expertise in drug delivery systems and tissue engineering [1][2][3] Company Overview - Decoy Therapeutics is a preclinical-stage biotechnology company focused on developing peptide-conjugate therapeutics targeting unmet medical needs, particularly in respiratory viruses and gastrointestinal cancers [8] - The company utilizes a proprietary IMP3ACT platform that integrates machine learning and AI for rapid design and synthesis of novel antiviral and cancer therapies [5][7] Scientific Advisory Board - Dr. Robert S. Langer's appointment to the Scientific Advisory Board is expected to enhance Decoy's capabilities in drug design and development, particularly in dosage forms and administration routes [3][4] - Dr. Langer's contributions to the field include pioneering work that has led to transformative medicines, such as Roche's Avastin and Moderna's Spikevax [2][4] Technology and Innovation - Decoy's IMP3ACT platform allows for the rapid computational design of peptide-conjugate drugs, which have shown effectiveness against various human coronaviruses and other viral pathogens [5][7] - The technology leverages peptide chemistry to create multimeric conjugates that improve drug-like properties and pharmacokinetics [7] Financial and Strategic Position - Decoy has secured financing from institutional investors and non-dilutive capital sources, including the Massachusetts Life Sciences Seed Fund and the Google AI startup program [8] - The merger with Salarius is structured such that Decoy investors will own approximately 86% of the merged company, while Salarius stockholders will own about 14% [10]

Core Viewpoint - Salarius Pharmaceuticals is progressing with its merger with Decoy Therapeutics, which is expected to enhance the clinical development of innovative peptide conjugate therapeutics targeting respiratory viruses and cancer [1][3][5] Financial Highlights - For the year ended December 31, 2024, Salarius reported a net loss of $5.6 million, or $5.79 per share, a significant reduction from a net loss of $12.5 million, or $30.74 per share in 2023 [8][17] - Cash and cash equivalents decreased to $2.4 million as of December 31, 2024, down from $5.9 million a year earlier [8][15] - Total operating expenses for 2024 were $5.7 million, compared to $12.9 million in 2023, reflecting a substantial decrease in research and development spending [17] Merger Details - The merger with Decoy Therapeutics is structured such that Decoy investors will own approximately 86% of the combined company, while Salarius stockholders will own about 14%, subject to adjustments [10] - The merger aims to leverage Decoy's IMPACT™ platform for rapid design and manufacturing of peptide conjugate therapeutics, addressing unmet needs in respiratory infectious diseases and gastrointestinal oncology [3][4] Product Development - Salarius' lead candidate, seclidemstat, is currently in a Phase 1/2 clinical trial at MD Anderson Cancer Center for treating hematologic cancers, with updates expected later this year [1][4][5] - The combined company plans to integrate Salarius' SP-3164 into a targeted peptide-based PROTACS drug candidate [4]